Skybiotech Healthcare Ltd

As of June 30, 2026, Skybiotech Healthcare Ltd carries a market capitalization of 429.86M, placing it among publicly traded companies globally. Its enterprise value stands at 429.86M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Skybiotech Healthcare Ltd has 2.24M shares outstanding.

These figures are as of June 30, 2026.

These figures are as of June 30, 2026. The EV/Sales ratio of 8.26 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 429.86M versus a market cap of 429.86M, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

Over the twelve months ended June 30, 2026, Skybiotech Healthcare Ltd recorded an income tax benefit of -5.50M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -22.22M and -16.72M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

These figures are as of the close on October 23, 2026.

Over the twelve months ended June 30, 2026, Skybiotech Healthcare Ltd generated 52.03M in revenue and converted that into -16.72M in net income, yielding earnings per share of -7.89. EBITDA reached -20.71M, while operating income came in at -25.36M.

Over the twelve months ended June 30, 2026, Skybiotech Healthcare Ltd posted a gross margin of 42.46, reflecting its pricing power and cost economics. The operating margin of -48.74 and net profit margin of -32.13 provide insight into operational efficiency.